piracetam has been researched along with Tuberous Sclerosis in 3 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Tuberous Sclerosis: Autosomal dominant neurocutaneous syndrome classically characterized by MENTAL RETARDATION; EPILEPSY; and skin lesions (e.g., adenoma sebaceum and hypomelanotic macules). There is, however, considerable heterogeneity in the neurologic manifestations. It is also associated with cortical tuber and HAMARTOMAS formation throughout the body, especially the heart, kidneys, and eyes. Mutations in two loci TSC1 and TSC2 that encode hamartin and tuberin, respectively, are associated with the disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levetiracetam appears to be effective in treatment-resistant seizures which are symptomatic to tuberous sclerosis when used adjunctively as well as in monotherapy." | 7.74 | Tuberous sclerosis successfully treated with levetiracetam monotherapy: 18 months of follow-up. ( Myrianthopoulou, P; Papacostas, SS; Papathanasiou, ES; Stylianidou, G, 2007) |
| "Levetiracetam was generally well tolerated, and adverse events were relatively uncommon in patients who responded to treatment." | 5.33 | Levetiracetam as adjunctive antiepileptic therapy for patients with tuberous sclerosis complex: a retrospective open-label trial. ( Chuck, G; Collins, JJ; Franz, DN; Leonard, JM; Tudor, C, 2006) |
| "Levetiracetam appears to be effective in treatment-resistant seizures which are symptomatic to tuberous sclerosis when used adjunctively as well as in monotherapy." | 3.74 | Tuberous sclerosis successfully treated with levetiracetam monotherapy: 18 months of follow-up. ( Myrianthopoulou, P; Papacostas, SS; Papathanasiou, ES; Stylianidou, G, 2007) |
| "Tuberous sclerosis or Tuberous Sclerosis Complex (TSC) is a genetic disorder characterized by the growth of numerous benign tumours in many parts of the body caused by mutations on either of two genes, TSC1 and TSC2." | 1.36 | Tuberous sclerosis. ( Syed, KN, 2010) |
| "Levetiracetam was generally well tolerated, and adverse events were relatively uncommon in patients who responded to treatment." | 1.33 | Levetiracetam as adjunctive antiepileptic therapy for patients with tuberous sclerosis complex: a retrospective open-label trial. ( Chuck, G; Collins, JJ; Franz, DN; Leonard, JM; Tudor, C, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Syed, KN | 1 |
| Collins, JJ | 1 |
| Tudor, C | 1 |
| Leonard, JM | 1 |
| Chuck, G | 1 |
| Franz, DN | 1 |
| Papacostas, SS | 1 |
| Papathanasiou, ES | 1 |
| Myrianthopoulou, P | 1 |
| Stylianidou, G | 1 |
3 other studies available for piracetam and Tuberous Sclerosis
| Article | Year |
|---|---|
Tuberous sclerosis.
Topics: Adult; Anticonvulsants; Carbamazepine; Female; Humans; Levetiracetam; Mutation; Piracetam; Tuberous | 2010 |
Levetiracetam as adjunctive antiepileptic therapy for patients with tuberous sclerosis complex: a retrospective open-label trial.
Topics: Adolescent; Adult; Anorexia; Anticonvulsants; Behavioral Symptoms; Child; Child, Preschool; Dose-Res | 2006 |
Tuberous sclerosis successfully treated with levetiracetam monotherapy: 18 months of follow-up.
Topics: Anticonvulsants; Child; Follow-Up Studies; Humans; Levetiracetam; Male; Piracetam; Seizures; Tuberou | 2007 |